首页 > 市场调查报告书 > 製药

以基因为基之药物开发

市场调查报告书

商品编码

1729317

日本药物基因组学市场报告（按技术、应用、最终用户和地区）2025-2033

Japan Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033

出版日期: 2025年05月01日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024 年，日本药物基因体学市场规模达 3.784 亿美元。展望未来， IMARC Group预计到 2033 年该市场规模将达到 6.711 亿美元，2025-2033 年期间的成长率 (CAGR) 为 6.08%。不断扩大的医疗保健基础设施、日益增长的老龄化人口、主要参与者持续的研究和开发 (R&D) 活动以及政府机构和医疗保健组织不断增加的教育倡议是推动市场发展的一些关键因素。

药物基因体学是研究基因如何影响个体对药物的反应的学科。这门科学学科结合了药理学（药物科学）和基因组学（研究基因及其功能）的元素。药物基因体学的主要目的是优化药物治疗，最大限度地提高疗效，同时最大限度地减少副作用。药物基因组学使得医疗方法更加个人化。它可以根据个人的基因组成来制定个人化的医疗治疗。这意味着可以针对每个人设计最适合的治疗方法，从而提高疗效。个人化治疗可以减轻医疗保健系统的财务负担。开药过程中的尝试和错误减少意味着患者可以更快地获得有效治疗，从而减少住院时间并降低整体医疗成本。药物基因组学还可以使製药公司受益，因为它可以确定新的药物靶点，并帮助开发更有效、更安全的药物，从而更快地获得监管部门的批准。

日本药物基因体学市场趋势：

日本拥有强大的医疗保健基础设施，以尖端技术和先进的研究设施为特点，正在推动日本市场的发展。日本在技术和医学领域的领先地位为药物基因组学的发展提供了有利的环境，并在研发方面投入了大量资金。此外，政府对基因组学研究的大力支持也为市场提供了支撑。监管政策和资金旨在鼓励个人化医疗（包括药物基因组学）的创新。日本政府已推出多项倡议，加速基因组学研究及其在医疗中的应用，从而为药物基因组学市场蓬勃发展创造良好的生态系统。日本人口老化也在扩大市场方面发挥关键作用。老年人更有可能有复杂的医疗保健需求和多种药物，使他们成为个人化治疗计划的理想人选。药物基因组学可以为这一人群提供有效且安全的优化药物疗法，减少药物不良反应，而药物不良反应是老年人住院的主要原因。此外，日本某些疾病的发生率相对较高，可以从药物基因组学应用中受益，包括各种类型的癌症和心血管疾病。针对这些常见疾病制定个人化治疗方案的能力可以改善治疗效果并降低医疗成本，从而使药物基因组学成为医疗保健提供者和患者都青睐的选择。此外，大众对个人化医疗益处的认识不断提高，也推动了市场的发展。此外，政府机构和医疗保健组织的教育措施也有助于人们更好地了解药物基因组学的优势，从而鼓励更多人选择此类测试和治疗。

日本药物基因组学市场细分：

技术洞察：

聚合酶炼式反应
微阵列
DNA定序
质谱法
电泳
其他的

应用程式洞察：

肿瘤学
传染病
心血管疾病
神经系统疾病
精神病学
疼痛管理
其他的

最终用户洞察：

医院和诊所
学术和研究机构

竞争格局：

市场研究报告也对市场竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本药物基因组学市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本药物基因体学市场有何影响？
日本药物基因体学市场根据技术如何划分？
日本药物基因体学市场根据应用如何划分？
根据最终用户，日本药物基因组学市场是如何分類的？
日本药物基因体学市场的价值链分为哪些阶段？
日本药物基因体学的主要驱动因素和挑战是什么？
日本药物基因体学市场的结构是怎么样的？主要参与者是谁？
日本药物基因体学市场的竞争程度如何？

本报告回答的关键问题：

日本药物基因组学市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本药物基因体学市场有何影响？
日本药物基因体学市场根据技术如何划分？
日本药物基因体学市场根据应用如何划分？
根据最终用户，日本药物基因组学市场是如何分類的？
日本药物基因体学市场的价值链分为哪些阶段？
日本药物基因体学的主要驱动因素和挑战是什么？
日本药物基因体学市场的结构是怎么样的？主要参与者是谁？
日本药物基因体学市场的竞争程度如何？

Japan pharmacogenomics market size reached USD 378.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 671.1 Million by 2033, exhibiting a growth rate (CAGR) of 6.08% during 2025-2033. The expanding healthcare infrastructure, increasing aging population, continual research, and development (R&D) activities by leading players, and rising educational initiatives by government bodies and healthcare organizations represent some of the key factors driving the market.

Pharmacogenomics is the study of how genes influence an individual's response to medications. This scientific discipline combines elements of pharmacology, which is the science of drugs, and genomics, which is the study of genes and their functions. The primary aim of pharmacogenomics is to optimize drug therapy, maximizing effectiveness while minimizing adverse effects. Pharmacogenomics allows for a more personalized approach to medicine. It allows for tailored medical therapy based on an individual's genetic makeup. This means that treatments can be specifically designed to work best for each person, enhancing effectiveness. Personalized treatment can reduce the financial burden on the healthcare system. Fewer trials and errors in prescribing medication mean that patients can potentially reach an effective treatment faster, reducing hospital stays and lowering overall healthcare costs. Pharmacogenomics can also benefit pharmaceutical companies by identifying new drug targets and assisting in the development of medication that is more effective and safer, which can lead to faster regulatory approval.

Japan Pharmacogenomics Market Trends:

The country's robust healthcare infrastructure, characterized by cutting-edge technology and advanced research facilities, is driving the market in Japan. Japan's reputation as a leader in the field of technology and medicine facilitates a supportive environment for the growth of pharmacogenomics, with significant investments in research and development. Moreover, the strong government support for genomics research is supporting the market. Regulatory policies and funding are geared towards encouraging innovations in personalized medicine, including pharmacogenomics. The Japanese government has launched several initiatives to accelerate research in genomics and its application in medical treatments, thereby creating a favorable ecosystem for the pharmacogenomics market to flourish. The aging population in Japan also plays a critical role in augmenting the market. Older individuals are more likely to have complex healthcare needs and multiple medications, making them ideal candidates for personalized treatment plans. Pharmacogenomics can offer optimized drug therapies that are both effective and safe for this demographic, reducing adverse drug reactions, which are a leading cause of hospitalization among the elderly. In addition, Japan has a relatively high incidence of certain diseases that can benefit from pharmacogenomic applications, including various types of cancer and cardiovascular disorders. The ability to tailor treatments for these prevalent conditions can improve outcomes and reduce healthcare costs, making pharmacogenomics an attractive option for both healthcare providers and patients. Furthermore, the market is fueled by increasing public awareness about the benefits of personalized medicine. Besides, educational initiatives by government bodies and healthcare organizations have also contributed to a greater understanding of the advantages of pharmacogenomics, thus encouraging more people to opt for such tests and treatments.

Japan Pharmacogenomics Market Segmentation:

Technology Insights:

Polymerase Chain Reaction
Microarray
DNA Sequencing
Mass Spectrometry
Electrophoresis
Others

Application Insights:

Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Diseases
Psychiatry
Pain Management
Others

End User Insights:

Hospitals and Clinics
Academic and Research Institutes

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pharmacogenomics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan pharmacogenomics market?
What is the breakup of the Japan pharmacogenomics market on the basis of technology?
What is the breakup of the Japan pharmacogenomics market on the basis of application?
What is the breakup of the Japan pharmacogenomics market on the basis of end user?
What are the various stages in the value chain of the Japan pharmacogenomics market?
What are the key driving factors and challenges in the Japan pharmacogenomics?
What is the structure of the Japan pharmacogenomics market and who are the key players?
What is the degree of competition in the Japan pharmacogenomics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacogenomics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pharmacogenomics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Pharmacogenomics Market - Breakup by Technology

6.1 Polymerase Chain Reaction
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Microarray
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 DNA Sequencing
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Mass Spectrometry
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Electrophoresis
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Pharmacogenomics Market - Breakup by Application

7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Infectious Diseases
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Neurological Diseases
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Psychiatry
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Pain Management
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Pharmacogenomics Market - Breakup by End User

8.1 Hospitals and Clinics
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Academic and Research Institutes
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)

9 Japan Pharmacogenomics Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Pharmacogenomics Market - Industry Analysis

11.1 Drivers, Restraints and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis